While ferroptosis-targeted clinical research in gastric cancer remains absent, systematic investigations of Erastin, RSL3, and the FSP1 pathway have yielded promising results in various solid tumors, establishing a preclinical research framework that integrates mechanisms, pharmacological agents, and combination strategies. Here, AIFM2 is linked to gastric cancer.